Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.32 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30593301 | 0.83 | KDM4E (0.43) | MAPT | |
| SCHEMBL25160236 | 0.74 | — | — | |
| SCHEMBL30602861 | 0.68 | MAPT (0.50) | MAPT | |
| SCHEMBL21845861 | 0.65 | KDM4E (0.37) | MAPT | |
| SCHEMBL20652846 | 0.63 | MAPT (0.51) | SLC5A1SLC5A2MAPT | |
| SCHEMBL25160033 | 0.63 | MAPT (0.51) | SLC5A1SLC5A2MAPT | |
| SCHEMBL23709213 | 0.63 | MAPT (0.51) | SLC5A1SLC5A2MAPT | |
| SCHEMBL12191943 | 0.63 | MAPT (0.51) | SLC5A1SLC5A2MAPT | |
| SCHEMBL25160112 | 0.62 | RGS4 (0.34) | SLC5A1SLC5A2MAPT | |
| SCHEMBL28115615 | 0.62 | MAOB (0.47) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3397629-B1 | METALLOENZYME INHIBITOR COMPOUNDS | NQP 1598 LTD (KY) | 2023-04-19 | — | — | EP | disclosed |
| US-10464922-B2 | Metalloenzyme inhibitor compounds | NQP 1598, LTD. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190016700-A1 | METALLOENZYME INHIBITOR COMPOUNDS | NQP 1598, LTD. (KY) | 2019-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190016700-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | NOTUM 1126/4885SLC5A1 989/4885SLC5A2 925/4885 |
| US-10464922-B2 | Metalloenzyme inhibitor compounds | MMEL1, GPX1, MPO | NOTUM 1126/4885SLC5A1 989/4885SLC5A2 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.